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Hiroshi Mabuchi1, Masakazu Yamagishi1 and Kenshi Hayashi1
1Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
2  Department of Clinical Laboratory Science, Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, 
Kanazawa University, Kanazawa, Japan
3Department of General Medicine, Kanazawa Medical University, Uchinada, Japan
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Aim: The Japan Atherosclerosis Society (JAS) guidelines for the prevention of atherosclerotic diseases 
2012 (JAS2012) proposed lipid management targets; however, less data is available regarding the 
attainment rates of each target in community-based settings. Therefore, we assessed the attainment 
rates of lipid management targets among subjects who underwent Japanese specific health checkups.
Methods: A total of 85,716 subjects (male?29,282, 34.2%) aged 40–74 years who underwent spe-
cific health checkups from 2012 to 2014 in Kanazawa city, Japan, were included in this study. We 
evaluated the attainment rates of the lipid management targets according to the JAS2012 guideline 
and investigated the clinical characteristics of the subjects without achieving the targets.
Results: The target for LDL cholesterol (LDL-C) was the least attained in all risk categories, 89, 72, 
50, and 34% for category ?, ?, ?, and secondary prevention, respectively, in 2014. In addition, 
these rates inversely correlated with the grade of risk categories (p-value for trends ?0.001). Attain-
ment rate of the LDL-C target in the suspected chronic kidney disease (CKD) group was signifi-
cantly lower than in the groups with diabetes, stroke, or absolute risk in category ? (49.2, 60.3, 
63.5, 54.4%, respectively, p-value ?0.001 for each). Moreover, the attainment rate of the LDL-C 
target was significantly lower in subjects that did not receive lipid-lowering therapy than in those 
who received it in the secondary prevention (27.7 and 40.6%, respectively, p-value ?0.001).
Conclusions: Lipid management is inadequate in community-based settings, particularly, in subjects 
with CKD and secondary prevention.
Key words:  JAS guideline 2012, LDL cholesterol, Specific health checkup
diseases in 2012 (JAS 2012), including lipid manage-
ment, dividing the subjects into four categories based 
on the absolute cardiovascular disease risk1). JAS2012 
has contributed to cardiovascular disease prevention in 
subjects with primary prevention as well as with sec-
ondary prevention. Several studies have shown that 
the attainment rates of lipid management targets were 
up to 50% in hospital-based settings2, 3). However, not 
much data is available regarding attainment rates in 
community-based settings. Therefore, we aimed to 
assess the attainment rates of lipid management tar-
Introduction
The Japan Atherosclerosis Society (JAS) has pro-
posed guidelines for the prevention of atherosclerotic 
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gets determined by JAS2012 among subjects who 
underwent specific health checkups initiated in com-
munity-based medical checkups in Japan.
Methods
Study Subjects
A total of 85,716 subjects (men?29,282, 34.2%) 
aged 40–74 years who underwent specific health 
checkups from 2012 to 2014 in Kanazawa city, Japan, 
and who had no missing data were included in this 
study. Most of the subjects visited general practitioners 
in clinics in Kanazawa city. All data were collected and 
anonymized by the Kanazawa Medical Association.
Ethical Considerations
This study was approved by the Ethics Commit-
tee of Kanazawa Medical Association and Kanazawa 
University and carried out in accordance with the 
Declaration of Helsinki (2008) of the World Medical 
Association. All procedures followed were in accor-
dance with the ethical standards of the responsible 
committee on human experimentation (institutional 
and national) and with the Helsinki Declaration of 
1975, as revised in 2008. Informed consent was 
obtained from all subjects for being included in the 
study.
Data collection in Specific Medical Checkup
Eligible participants visited a clinic and 
responded to a questionnaire regarding past history of 
stroke, cardiac disease, kidney disease, lifestyle habits, 
such as smoking, alcohol intake, walking, and medica-
tions for hypertension, diabetes, and dyslipidemia. 
Measurements included standard medical checks, such 
as measurement of height, weight, waist circumfer-
ence, blood pressure, fasting blood glucose, hemoglo-
bin A1c, total cholesterol, triglyceride, serum high-
density lipoprotein (HDL) cholesterol (HDL-C), low-
density lipoprotein (LDL) cholesterol (LDL-C), serum 
creatinine, dipstick urine test for proteinuria, hematu-
ria, and urinary sugar. Proteinuria was coded as nega-
tive, plus and minus, 1 plus, 2 plus, and 3 plus. Serum 
creatinine levels were measured using the enzymatic 
method. Glomerular filtration rate was calculated 
using the formula of the Japanese Society of Nephrol-
ogy4). Hypertension was defined as a blood pressure of 
≥ 140/90 mmHg or if the subject was receiving hypo-
tensive medication. Diabetes was defined as the 
patient having 1) hemoglobin A1c ≥ 6.5% and blood 
glucose ≥ 126 at fasting, 2) hemoglobin A1c ≥ 6.5% 
and blood glucose ≥ 200 at non-fasting, or 3) hypo-
glycemic medication. The presence of suspected 
chronic kidney disease (CKD) was defined according 
to the CKD classification based on the combination 
of estimated glomerular filtration rate (eGFR) and 
dipstick proteinuria findings5). We could not defini-
tively determine the presence of CKD based on our 
cross-sectional design, although the definition of 
CKD includes a situation where kidney injury contin-
ues for over 3 months. Accordingly, we investigated 
the proportion of subjects fulfilling this CKD criteria 
at least twice for the subjects suspected as having 
CKD in 2012. Of these, only the subjects whose fol-
low-up data were available either in 2013 or in 2014 
were included to validate our inclusion criteria as 
CKD.
Risk Assessments and Categorization According to 
JAS Guideline 2012
Next, we classified subjects into four categories 
according to the JAS2012. The methodology of the 
risk classification procedure according to the JAS2012 
has been described previously1). Briefly, subjects were 
assessed if they were secondary prevention cases with 
any histories of coronary artery disease (CAD). If not, 
then they were assigned to risk category ? when the 
following criteria were fulfilled: (1) diabetes, (2) sus-
pected CKD, and (3) non-cardiogenic cerebral infarc-
tion. After these assignments, remaining subjects were 
assigned to risk categories ?, ?, and ? based on the 
absolute risk of CAD death estimated by NIPPON-
DATA 806) and on the existence of an additional risk 
factor (hypo-HDL cholesterolemia).
Evaluations
We evaluated the attainment rates of the lipid 
management targets according to the JAS2012 guide-
lines for each risk category and compared these rates 
among each category. We employed LDL-C values 
calculated using the Friedewald formula if the mea-
surements were of fasting and TG ?400 mg/dl. Oth-
erwise, we used LDL-C values directory measured. In 
addition, we investigated the trends of those attain-
ment rates from 2012 to 2014. Furthermore, we 
investigated the characteristics of the subjects who did 
not attain the LDL-C target.
Statistical Analysis
Jonckheere-Terpstra trend test was used to assess 
the trends of the attainment rates among each cate-
gory. The chi-squared test was used to compare the 
attainment rates over time. P-value ?0.05 was con-
sidered statistically significant, and all tests were two-





Characteristics of Study Subjects
Clinical characteristics of study subjects are 
shown in Tables 1-3. As expected, category ? com-
prises younger subjects than present in any other cate-
gories (p-value ?0.001). In addition, we observed sig-
nificant trends in category ?, ?, ?, and secondary 
prevention for other basic characteristics, such as, sex 
(the proportion of male?17.6, 28.1, 46.1, and 
52.4%, respectively, in 2014, p-value for trend ?
0.001), body mass index (mean?21.9, 22.4, 23.4, 
and 23.4 kg/m2, respectively, in 2014, p-value for 
trend ?0.001), and waist circumference (mean?78.9, 
81.9, 84.5, and 84.9 cm, respectively, in 2014, p-value 
for trend ?0.001). As much as a quarter of the sub-
jects were classified as having suspected CKD.
Attainment Rates for Lipid Management Targets
Attainment rates for lipid management targets 
are illustrated in Fig.1-3. In 2012, when the current 
guideline was introduced, the attainment rate of all 
four lipid management targets (LDL-C, TG, HDL-C, 
and non-HDL-C) for all the study subjects was 
51.5%. When divided into four categories based on 
JAS2012, an inverse correlation was observed in the 
attainment rates of all four lipid management targets 
according to the category (76.3, 60.7, 35.8, and 
24.2%, in category ?, ?, ?, and secondary preven-
tion, respectively, p-value for trend ?0.001). Among 
the four different targets, LDL-C management target 
was the least attained (67.3%). Similar to the overall 
trend, an inverse correlation was observed in the 
attainment rate of LDL-C management target accord-
ing to the category (90.4, 75.7, 54.3, and 35.2%, in 
category ?, ?, ?, and secondary prevention, respec-
tively, p-value for trend ?0.001). In 2013, the overall 
attainment rate of all the four lipid management tar-
gets was 52.0%. An inverse correlation was observed 
in the attainment rates of all the four lipid manage-
ment targets according to the category (78.3, 60.0, 
33.6, and 25.0%, in category ?, ?, ?, and secondary 
prevention, respectively, p-value for trend ?0.001) in 
2012. Further, an inverse correlation was observed in 
the attainment rates of LDL-C management target 
according to the category (89.6, 74.3, 51.6, and 36.1, 
in category ?, ?, ?, and secondary prevention, 
respectively, p-value for trend ?0.001). In 2014, we 
observed the same overall trends (75.9, 57.3, 33.5, 
and 23.2%, in category ?, ?, ?, and secondary pre-
vention, respectively, p-value for trend ?0.001), as 
well as in LDL-C (89.1, 71.5, 50.0, and 34.3%, in 
category ?, ?, ?, and secondary prevention, respec-
tively, p-value for trend ?0.001). We could not 
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observe any significant increases in attainment rates in 
all of lipid management targets (LDL-C, triglyceride, 
and HDL-C), from 2012 to 2014.
Characteristics of the Subjects that did not Achieve 
the Targets in Category ? and Secondary Prevention 
Cases
Next, we investigated the characteristics of the 
subjects who did not attain the management targets, 
particularly, LDL-C targets using data in 2014 that 
were the latest and the largest. In category ?, the 
highest risk category in the primary prevention, as 
many as 5,018 subjects (50.0%) did not attain the 
LDL-C management target. Among them, as many as 
3,392 (67.6%) subjects exhibited CKD (Table 4). 













































LDL-C HDL-C TG Non-HDL-C All
Fig.1. Attainment rates for lipid management targets (2012)













































LDL-C HDL-C TG Non-HDL-C All
Fig.2. Attainment rates for lipid management targets (2013)
Light blue: LDL-C, Orange: HDL-C, Gray: TG, Yellow: Non-HDL-C, Blue: All
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pected CKD group was significantly lower than in the 
group with diabetes, stroke, or absolute risk in cate-
gory ? (49.2% vs. 60.3, 63.5, and 54.4%, respec-
tively, p-value ?0.001 for each comparison, Table 4). 
Moreover, the attainment rate of the LDL-C target 
was significantly lower in subjects who did not receive 
lipid-lowering therapy than in those who did as the 
secondary prevention (27.7 and 40.6%, respectively, 
p-value ?0.001, Table 5).
Validation of Suspected CKD as a Substitute for 
CKD
Among the 6,927 subjects suspected of having 
CKD in 2012, 4,577 (66.1%) subjects were followed-
up either in 2013 or in 2014. We found that 4,236 
(92.5%) fulfilled the criteria of CKD diagnosis. 
Discussion
Using a large dataset from the community-based 
Table 4. Comparison of attainment rates of the LDL-C target among risks in category ?
? All (N) Attained LDL-C target 
(N, %)























CKD: Chronic kidney disease, LDL-C: LDL cholesterol
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Fig.3. Attainment rates for lipid management targets (2014)




specific medical check-ups, we found that 1) the 
attainment rates of all the four lipid management tar-
gets were approximately 50%, 2) the targets of LDL-C 
were overall the least attained (65%), 3) there were 
significant inverse trends in the attainment rate of 
LDL-C management target according to the category, 
4) the attainment rate of the LDL-C target in the 
group with CKD was significantly lower than in the 
group with diabetes, stroke, or absolute risk in cate-
gory ?, 5) the attainment rate of the LDL-C target 
was significantly lower in subjects who did not receive 
lipid-lowering therapy than in those who did as the 
secondary prevention, and 6) such trends did not 
change from 2012 to 2014.
In 1992, JAS proposed the initial guideline for 
the diagnosis and treatment of hyperlipidemia in 
adults, which is revised every 5 years. These revisions 
have adopted a number of updated clinical interven-
tional trials and observational cohort studies7-9). On 
the other hand, only little data investigating the 
attainment rates of target established by such guide-
lines are available, most of which are from hospital-
based settings2, 3). However, a larger proportion of Jap-
anese population is treated by general practitioners in 
the community; thus, it is vital to expand such studies 
to community-based settings. Since 2008, commu-
nity-based medical checkups named “specific health 
checkups” have been started in Japan considering our 
aging society and increases in lifestyle-related diseases. 
Specific health checkups have great advantages such as 
financial support provided from the government to a 
large number of participants and the uniformity of the 
investigated items10, 11). In this study, we used the 
dataset collected in Kanazawa city, Japan, which has a 
population of approximately 500,000. 
The proportions of the subjects who attained the 
LDL-C targets seem to be lower than those previously 
investigated in hospital-based settings. It is reasonable 
to see such differences, since the subjects who are 
treated in hospitals should have much more complica-
tions than those treated in clinics in communities, 
leading to their more intensive therapies. 
It is of note that the subjects with suspected 
CKD, classified into category ?, were quite under-
treated, although known to be highly associated with 
CAD12), and that the majority of secondary preven-
tion cases without achieving LDL-C target did not 
receive any lipid-lowering therapies. Furthermore, 
such trends unchanged during the study period 
despite of the intensive effort of enlightenment of this 
guideline by JAS, at least in community-based set-
tings. It seems that general practitioners in the com-
munity tended to treat patients aiming for the normal 
range (LDL-C?120 to 140 mg/dl), rather than to 
attain the targets determined by the guideline. The 
concept of “the lower, the better” in LDL-C level has 
been widely accepted, and such a situation will be 
achievable using new drugs, such as proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) inhibitor13). 
However, awareness itself to attain the current target 
should be the first step in the prevention of CAD.
This study has several limitations. First, this 
study investigated the population living in Kanazawa 
area, not using nation-wide dataset, which could 
potentially affect the results. However, we believe that 
large sample size could dilute such bias. Second, infor-
mation of peripheral artery disease, family history of 
premature CAD, and impaired glucose tolerance are 
lacking in our data, which could potentially underesti-
mate the risk category. However, such underestima-
tions of risk category do not likely to reduce the pro-
portions of undertreated subjects in category ? nor in 
secondary prevention cases. Third, the definition of 
diabetes includes only “definite” diabetes, leaving the 
possibility of missing subjects who require oral glucose 
tolerance and other diagnostic tests. In addition, we 
could not determine definite CKD because of the 
cross-sectional nature of the study design. However, 
we found that most subjects suspected as having CKD 
eventually fulfilled the criteria of CKD, and thus, the 
essential conclusions of this study would not change. 
Fourth, a fair proportion of subjects exhibited hyper 
LDL- cholesterolemia ≥ 180 mg/dl (~4% of the sub-
jects), among whom there should be some patients 
with familial hypercholesterolemia (FH) whose lipid 
management targets are set more strictly. In this 
regard, we need to consider special notification of pos-
sibility for FH in the reports, since the prevalence of 
FH in general population has been shown to be more 
frequent than previously considered14). Fourth, large 
proportions of individuals were receiving checkups 
regularly (17,734 among 29,002 [61%] individuals 
were overlapped between 2012 and 2013, and 18,298 
among 29,334 [62%] individuals were overlapped 
between 2013 and 2014), which could lead some 
potential bias. However, this fact rather makes us con-
fident that the attainment rates of lipid management 
target unchanged during these periods. Finally, 
detailed information regarding lipid-lowering thera-
pies is lacking in this study. However, we want to 
emphasize the fact that high-risk patients in category 
? or in secondary prevention group are not treated 
adequately, instead of the way of treatment. 
In conclusion, lipid management is inadequate 
in the community-based settings, especially in the 
subjects with CKD and secondary prevention cases. 
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